Proteostasis Therapeutics (PTI) Receives Daily News Sentiment Rating of -0.02
News coverage about Proteostasis Therapeutics (NASDAQ:PTI) has been trending somewhat negative recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Proteostasis Therapeutics earned a coverage optimism score of -0.02 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.5498351112048 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Contrasting Proteostasis Therapeutics (PTI) & The Competition (americanbankingnews.com)
- Proteostasis Therapeutics Inc (PTI) Expected to Announce Quarterly Sales of $1.59 Million (americanbankingnews.com)
- -$0.65 Earnings Per Share Expected for Proteostasis Therapeutics Inc (PTI) This Quarter (americanbankingnews.com)
- FY2018 EPS Estimates for Proteostasis Therapeutics Inc (PTI) Lifted by Leerink Swann (americanbankingnews.com)
Several brokerages have commented on PTI. Leerink Swann reaffirmed an “outperform” rating and issued a $9.00 price target (down previously from $17.00) on shares of Proteostasis Therapeutics in a research report on Wednesday, August 16th. Zacks Investment Research lowered Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 18th.
Proteostasis Therapeutics (NASDAQ PTI) traded down $0.12 during trading on Friday, hitting $2.41. The company’s stock had a trading volume of 65,332 shares, compared to its average volume of 186,912. Proteostasis Therapeutics has a 1-year low of $1.41 and a 1-year high of $16.67.
Proteostasis Therapeutics (NASDAQ:PTI) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.16. The company had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.38 million. Proteostasis Therapeutics had a negative return on equity of 93.15% and a negative net margin of 712.49%. equities research analysts anticipate that Proteostasis Therapeutics will post -2.47 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Proteostasis Therapeutics (PTI) Receives Daily News Sentiment Rating of -0.02” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/proteostasis-therapeutics-pti-receives-daily-news-sentiment-rating-of-0-02/1756117.html.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.